Nesepolyper (CRSwNP)
Artikler
DUPIREAL: Two-Year Turning Point with Dupilumab in CRSwNP
The results from the DUPIREAL real-world study reinforce the efficacy of dupilumab demonstrated in the SINUS-24 and SINUS-52 randomized clinical trials and are consistent with the approved SmPC.1,2,3,4 DUPIREAL is the largest long-term real-world study (n=926) evaluating the effectiveness of dupilumab, including treatment response, disease control and remission, in severe uncontrolled CRSwNP over 2 years.2,3
Real-World Evidence and Phase IV studies in CRSwNP
Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burden and poor health-related quality of life (QoL), often requiring recurring systemic corticosteroid use and repeated sinus surgery.
EVEREST study: First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma
First ever direct Head-to-Head Comparison of Dupilumab vs Omalizumab in Patients with Severe CRSwNP and Coexisting Asthma.
Uncovering the Hidden Burden: Understanding Loss of Smell in CRSwNP
Navigating the Complexities of Smell Loss in Patients with CRSwNP.